Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

Pages

33 results
10:21 AM, Apr 13, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Abpro planning $69M NASDAQ listing

to develop it to treat HER2-positive solid tumors in Orphan indications. ABP-201 targets VEGF and angiopoietin 2
ANG2; ANPT2). The company intends to develop that antibody to treat vascular diseases of the eye …
12:35 PM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
8:08 PM, Dec 14, 2017  |  BC Week In Review | Clinical News  |  Regulatory

FDA accepts Regeneron's sBLA for 12-week Eylea dosing

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted an sBLA for a quarterly dosing schedule of Eylea aflibercept to treat wet age-related macular degeneration (AMD). Its PDUFA date is Aug. 11, 2018. The drug is already...
1:42 PM, Dec 01, 2017  |  BC Week In Review | Clinical News  |  Clinical Status

Regeneron to discontinue nesvacumab/Eylea combo

data from the trials before deciding on how to proceed with nesvacumab, a mAb against angiopoietin 2
ANG2; ANGPT2). He said Regeneron has not disclosed whether the candidate is in testing for other …
Tarrytown, N.Y.  Bayer AG (Xetra:BAYN), Leverkusen, Germany  Product: Nesvacumab (REGN910, SAR307746)  Business: Cancer  Molecular target: Angiopoietin 2
1:49 PM, Dec 02, 2016  |  BC Week In Review | Company News  |  Deals

Abpro, AstraZeneca deal

LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2
ANG2 ; ANGPT2) and VEGF for multiple undisclosed indications. Abpro will use its DiversImmune platform …
12:00 AM, Mar 28, 2016  |  BC Week In Review | Company News  |  Deals

Regeneron, Bayer deal

commercialization rights and will retain all profits from U.S. sales. Nesvacumab is a mAb against angiopoietin 2
ANG2 ; ANGPT2 ), and Eylea is a human fusion protein that binds all forms …
12:00 AM, Feb 08, 2016  |  BC Week In Review | Clinical News  |  Clinical Status

Anti-VEGF/Ang2 Nanobody: Phase I started

BI 836880 )   Business: Cancer   Molecular target: Vascular endothelial growth factor (VEGF); Angiopoietin 2
ANG2) (ANGPT2)   Description: Bispecific Nanobody targeting VEGF and angiopoietin 2 (ANG2; ANGPT2)   Indication: Treat advanced …
12:00 AM, Nov 10, 2014  |  BC Week In Review | Clinical News  |  Clinical Results

Trebananib: Additional Phase III data

AMG 386 )   Business: Cancer   Molecular target: Angiopoietin 1 (ANG1) (ANGPT1) ; Angiopoietin 2
ANG2) (ANGPT2)   Description: Recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins   Indication: Treat recurrent ovarian …
12:00 AM, Jun 30, 2014  |  BC Week In Review | Clinical News  |  Clinical Results

MEDI3617: Phase I data

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.   Product: MEDI3617   Business: Cancer   Molecular target: Angiopoietin 2
ANG2) (ANGPT2)   Description: Anti-angiopoietin 2 (ANG2; ANGPT2) mAb   Indication: Treat advanced solid tumors   Endpoint …
12:00 AM, Jun 17, 2013  |  BC Week In Review | Clinical News  |  Clinical Results

Trebananib: Phase III data

AMG 386 )   Business: Cancer   Molecular target: Angiopoietin 1 (ANG1) (ANGPT1) ; Angiopoietin 2
ANG2) (ANGPT2)   Description: Recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins   Indication: Treat recurrent ovarian …

Pages